EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Personalization of thiopurine therapy: Current recommendations and future perspectives

Dunja Urbančič iD, Flaka Pasha iD, Alenka Šmid iD, Irena Mlinarič-Raščan iD

Acta Pharmaceutica · 2024

DOI: 10.2478/acph-2024-0030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica, 2024. Verfasst von Dunja Urbančič und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Ljubljana, Faculty of Pharmacy, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Precision Medicine, Methyltransferases, Mercaptopurine, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 ( NUDT15 ) and thiopurine S -methyltransferase ( TPMT ) genotype, along side thiopurine S -methyltransferase activity and thiopurine metabolic profile. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmaco genomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, meta bolic, and clinical factors to further individualize thiopurine therapy is highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineMethyltransferasesMercaptopurineInflammatory Bowel DiseasesHumansAzathioprinePharmacogeneticsPyrophosphatasesAutoimmune DiseasesNeoplasmsGenotypeThioguanineNudix Hydrolases

Stichwörter der Autor:innen

NUDT15TPMTpersonalized medicinetherapeutic drug monitoringthiopurines

Substanzen

MethyltransferasesMercaptopurineAzathioprinePyrophosphatasesNUDT15 protein, humanThioguanineTPMT protein, humanNudix Hydrolases

Autor:innen und Institutionen

  • University of Ljubljana, Faculty of Pharmacy, 1000 Ljubljana, Slovenia.
  • University of Prishtina "Hasan Prishtina", Faculty of Medicine Department of Pharmacology with Toxicology, and Clinical Pharmacology 10000 Prishtina, Kosovo.

ORCID-Profile: Dunja Urbančič, Flaka Pasha, Alenka Šmid, Irena Mlinarič-Raščan

Zitieren

APA

Urbančič, D., Pasha, F., Šmid, A., & Mlinarič-Raščan, I. (2024). Personalization of thiopurine therapy: Current recommendations and future perspectives. Acta Pharmaceutica. https://doi.org/10.2478/acph-2024-0030

Vancouver

Urbančič D, Pasha F, Šmid A, Mlinarič-Raščan I. Personalization of thiopurine therapy: Current recommendations and future perspectives. Acta Pharmaceutica. 2024. doi:10.2478/acph-2024-0030

BibTeX
@article{Urbani2024,
  author = {Urbančič, Dunja and Pasha, Flaka and Šmid, Alenka and Mlinarič-Raščan, Irena},
  title = {Personalization of thiopurine therapy: Current recommendations and future perspectives},
  journal = {Acta Pharmaceutica},
  year = {2024},
  doi = {10.2478/acph-2024-0030}
}
Kostenlos starten →